Summary on Performance, People, Planet

In 2019, Clariant decided to dispose the Business Units and Pigments. The two Business Units concerned have been reclassified to discontinued operations in the financial reporting. Clariant’s Integrated Report 2019 follows this structure for selected figures and separately reports on continuing and discontinued operations.

Performance

Financial Capital in CHF m

 

 

Continuing
operations

 

Discontinued
operations

 

Total 2019

 

2018

1

Contains the contribution to growth of the innovation portfolio from both Top Line Innovation and Life Cycle Innovation. Potential cannibalization of existing sales by Life Cycle Innovation has not been excluded.

2

Including own employees and external staff

Sales

 

4 399

 

2 127

 

6 526

 

6 623

EBITDA before exceptional items

 

740

 

203

 

943

 

1 018

EBITDA after exceptional items

 

461

 

158

 

619

 

871

EBITDA margin before exceptional items (%)

 

16.8

 

9.5

 

14.4

 

15.4

EBITDA margin after exceptional items (%)

 

10.5

 

7.4

 

9.5

 

13.2

EBIT before exceptional items

 

444

 

168

 

612

 

693

EBIT after exceptional items

 

165

 

124

 

289

 

546

Net income

 

–34

 

72

 

38

 

356

Basic earnings per share (in CHF)

 

–0.17

 

0.20

 

0.03

 

1.02

Adjusted earnings per share (in CHF)

 

0.87

 

 

 

 

 

1.50

Operating cash flow

 

 

 

 

 

509

 

530

Investment in property, plant, and equipment

 

 

 

 

 

273

 

237

Research & Development expenditures

 

 

 

 

 

207

 

209

Growth through innovation (%)1

 

>3.5

 

<0.5

 

<3.0

 

>3.0

Personnel expenditures2

 

1 068

 

410

 

1 478

 

1 518

Raw material procurement

 

1 758

 

884

 

2 642

 

2 948

Total assets

 

6 681

 

1 298

 

7 979

 

7 981

Equity

 

 

 

 

 

2 677

 

2 970

Equity ratio (%)

 

 

 

 

 

33.6

 

37.2

Net debt

 

 

 

 

 

1 372

 

1 374

Gearing ratio (%)

 

 

 

 

 

51

 

46

Intellectual Capital

 

 

Continuing
operations

 

Discontinued
operations

 

Total 2019

 

2018

Patents (year-end)

 

>5 400

 

>1 100

 

>6 500

 

6 700

Active innovation projects

 

>315

 

>60

 

>375

 

>375

Of which Class 1 Projects with double-digit million sales potential or of strategic relevance

 

>60

 

>5

 

>65

 

>70

Scientific collaborations

 

 

 

 

 

>125

 

>125

Manufactured Capital

 

 

Continuing
operations

 

Discontinued
operations

 

Total 2019

 

2018

1

For 2018 and 2019, the production volume is based on a reduced reporting scope, which includes sites that are responsible for 95% of total production.

Research & Development Centers

 

 

 

 

 

8

 

8

Technical Centers

 

 

 

 

 

>50

 

>50

Production sites

 

66

 

52

 

118

 

125

Countries with production facilities

 

 

 

 

 

38

 

39

Raw materials procured (in m t)

 

2.79

 

0.34

 

3.13

 

3.57

Production (in m t)1

 

3.99

 

0.26

 

4.25

 

4.34

People

Human Capital in FTE (Full-time Equivalents)

 

 

Continuing
operations

 

Discontinued
operations

 

Total 2019

 

2018

1

Restated due to one reclassified injury, which was not considered by the statutory insurer as an incident but determined to be a personal health issue.

Total staff

 

11 941

 

5 282

 

17 223

 

17 901

Employees

 

7 510

 

2 649

 

10 159

 

10 405

Of which male

 

4 939

 

1 955

 

6 894 (68%)

 

7 115 (68%)

Of which female

 

2 571

 

694

 

3 265 (32%)

 

3 290 (32%)

Workers

 

4 431

 

2 633

 

7 064

 

7 496

Of which male

 

4 065

 

2 538

 

6 603 (93%)

 

6 890 (92%)

Of which female

 

366

 

95

 

461 ( 7%)

 

606 ( 8%)

Total training hours

 

167 150

 

38 711

 

205 861

 

234 240

Training hours (Ø per participant)

 

16.7

 

10.0

 

14.8

 

15

Staff in Research & Development

 

>960

 

>90

 

>1 050

 

>1 100

Lost Time Accident Rate (LTAR: accidents with at least 1 day lost/200 000 work hours)

 

0.15

 

0.13

 

0.15

 

0.141

Relationship Capital

 

 

Continuing
operations

 

Discontinued
operations

 

Total 2019

 

2018

1

Survey is conducted every two years.

2

Duplicate counts possible. One supplier may supply to continuing and discontinued operations.

Employee participation in engagement survey

 

 

 

 

 

n.a.1

 

2 466

Raw material suppliers2

 

3 503

 

3 896

 

6 805

 

7 000

Raw material supply base by spend covered by sustainability evaluations (%)

 

80

 

74

 

78

 

74

Survey responses obtained from customer contacts

 

 

 

 

 

n.a.1

 

2 791

Customers who want to continue doing business with Clariant (%)

 

 

 

 

 

n.a.1

 

90

Planet

Natural Capital1

 

 

Continuing
operations

 

Discontinued
operations

 

Total 20192

 

2018

1

Every three years, Clariant validates environmental data from all production sites. The last full reporting campaign was in 2017. In the interim years, including 2018 and 2019, the reduced reporting Scope comprises the larger sites responsible for 95% of production.

2

The difference in the sum of continued and discontinued operations compared to the group total is due to the resource consumption of non-production sites.

Total energy consumption (in m kWh)

 

2 400

 

652

 

3 058

 

3 209

Energy consumption (in kWh/t production)

 

601

 

2 547

 

720

 

739

Total water consumption (in m m3)

 

25.7

 

17.3

 

44.3

 

49.0

Total wastewater generation (in m m3)

 

6.7

 

3.7

 

11.9

 

12.6

Total greenhouse gas emissions (Scope 1 & 2 CO2 equivalents) (in m t)

 

0.68

 

0.16

 

0.84

 

0.93

Total indirect greenhouse gas emissions (Scope 3 CO2 equivalents) (in m t)

 

 

 

 

 

4.99

 

5.69

Greenhouse gas emissions (Scope 1 & 2 CO2 equivalents) (in kg/t production)

 

171

 

609

 

198

 

215

Total quantity of waste (in thousand t)

 

215.7

 

32.6

 

250.2

 

232

Masterbatches

These are plastic additives in the form of granules with dyestuffs or other additives used to dye or alter the properties of natural plastic. View entire glossary

FURTHER READING